News, Mannkind Stays Positive on Inhaled Insulin Despite FDA Delays. (blood)

[JD59]

The Burrill Report submits: The long road to approval for Mannkind's (MNKD) Afrezza inhaled insulin got a little longer March 15, as the FDA asked for more information to support its review of the drug. Afrezza is a powdered insulin for helping adult patients with type 1 and type 2 diabetes mellitus control high blood glucose, also known as hyperglycemia, which is a major cause of diabetes-related complications.

Mannkind Stays Positive on Inhaled Insulin Despite FDA Delays | www.bullfax.com

[litlux]

Thanks for posting this. I have been following the development, and have been concerned that they see the approval process as a nuisance, rather than as questions that absolutely should be asked and conclusively answered before people begin breathing in a new powdered substance on a regular basis.

The release (and the media it appears in) seems to suggest that they are more interested in the money than those they will sell this to. I have already decided that this company does not have my best interests as a diabetic at heart.

I hope they prove me wrong in the end, but this announcement does not instill much confidence.

[RI360]

Check out this site below:
[url]https://www.retailinvestor360.com/[/url]

There are more articles on Mannkind, such as
[url]https://www.retailinvestor360.com/biotech/256-a-featured-presentation-on-mannkind-corporation-s-revolutionary-diabetes-treatment.html?highlight=WyJtYW5ua2luZCIsIm1hbm5ra W5kJ3MiXQ==[/url]